Nie Q, Liang Q, Li M, Zhu R, Ren J, Jiang K
Medicine (Baltimore). 2024; 103(51):e40642.
PMID: 39705493
PMC: 11666171.
DOI: 10.1097/MD.0000000000040642.
Shukla A, Rockey D, Kamath P, Kleiner D, Singh A, Vaidya A
Hepatol Int. 2024; 18(6):1684-1711.
PMID: 39546143
DOI: 10.1007/s12072-024-10739-6.
Premkumar M, Anand A
J Clin Exp Hepatol. 2024; 14(5):101396.
PMID: 38601747
PMC: 11001647.
DOI: 10.1016/j.jceh.2024.101396.
Philips C, Ahamed R, Abduljaleel J, Rajesh S, Theruvath A, Raveendran R
Oxf Med Case Reports. 2022; 2022(10):omac113.
PMID: 36299672
PMC: 9589464.
DOI: 10.1093/omcr/omac113.
Santra A, Bishnu D, Santra S, Ghatak S, Mukherjee P, Dhali G
Int J Hepatol. 2022; 2022:1546297.
PMID: 36117518
PMC: 9477643.
DOI: 10.1155/2022/1546297.
Hepatorenal Toxicity of Inorganic Arsenic in White Pekin Ducks and Its Amelioration by Using Ginger.
Panda S, Kumar D, Jena G, Patra R, Panda S, Sethy K
Biol Trace Elem Res. 2022; 201(5):2471-2490.
PMID: 35723853
DOI: 10.1007/s12011-022-03317-0.
Estimation of Trace Elements, Antioxidants, and Antibacterial Agents of Regularly Consumed Indian Medicinal Plants.
Swain S, Rautray T
Biol Trace Elem Res. 2020; 199(3):1185-1193.
PMID: 32529470
DOI: 10.1007/s12011-020-02228-2.
Idiopathic noncirrhotic portal hypertension: current perspectives.
Riggio O, Gioia S, Pentassuglio I, Nicoletti V, Valente M, dAmati G
Hepat Med. 2016; 8:81-8.
PMID: 27555800
PMC: 4968980.
DOI: 10.2147/HMER.S85544.
Arsenicosis, possibly from contaminated groundwater, associated with noncirrhotic intrahepatic portal hypertension.
Goel A, Christudoss P, George R, Ramakrishna B, Amirtharaj G, Keshava S
Indian J Gastroenterol. 2016; 35(3):207-15.
PMID: 27225799
DOI: 10.1007/s12664-016-0660-1.
Idiopathic non-cirrhotic portal hypertension: a review.
Schouten J, Verheij J, Seijo S
Orphanet J Rare Dis. 2015; 10:67.
PMID: 26025214
PMC: 4457997.
DOI: 10.1186/s13023-015-0288-8.
Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis.
Goel A, Ramakrishna B, Muliyil J, Madhu K, Sajith K, Zachariah U
Dig Dis Sci. 2012; 58(1):179-87.
PMID: 22918688
DOI: 10.1007/s10620-012-2361-7.
Arsenic decreases RXRα-dependent transcription of CYP3A and suppresses immune regulators in hepatocytes.
Noreault-Conti T, Fellows A, Jacobs J, Trask H, Strom S, Evans R
Int Immunopharmacol. 2012; 12(4):651-6.
PMID: 22310326
PMC: 3345897.
DOI: 10.1016/j.intimp.2012.01.008.
Oxidative stress and hepatic stellate cell activation are key events in arsenic induced liver fibrosis in mice.
Ghatak S, Biswas A, Dhali G, Chowdhury A, Boyer J, Santra A
Toxicol Appl Pharmacol. 2010; 251(1):59-69.
PMID: 21134390
PMC: 3745774.
DOI: 10.1016/j.taap.2010.11.016.
Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors.
Eapen C, Nightingale P, Hubscher S, Lane P, Plant T, Velissaris D
Dig Dis Sci. 2010; 56(1):227-35.
PMID: 20499175
DOI: 10.1007/s10620-010-1278-2.
Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment.
Sarin S, Kumar A, Chawla Y, Baijal S, Dhiman R, Jafri W
Hepatol Int. 2009; 1(3):398-413.
PMID: 19669336
PMC: 2716836.
DOI: 10.1007/s12072-007-9010-9.
Liver is a target of arsenic carcinogenesis.
Liu J, Waalkes M
Toxicol Sci. 2008; 105(1):24-32.
PMID: 18566022
PMC: 2734307.
DOI: 10.1093/toxsci/kfn120.
Patient with hepatocellular carcinoma related to prior acute arsenic intoxication and occult HBV: epidemiological, clinical and therapeutic results after 14 years of follow-up.
Casanovas-Taltavull T, Ribes J, Berrozpe A, Jordan S, Casanova A, Sancho C
World J Gastroenterol. 2006; 12(12):1972-4.
PMID: 16610011
PMC: 4087530.
DOI: 10.3748/wjg.v12.i12.1972.
Pathology related to chronic arsenic exposure.
Centeno J, Mullick F, Martinez L, Page N, Gibb H, Longfellow D
Environ Health Perspect. 2002; 110 Suppl 5:883-6.
PMID: 12426152
PMC: 1241266.
DOI: 10.1289/ehp.02110s5883.